You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 9,504,744

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,504,744

Title:	Treatment of diffuse large-cell lymphoma with anti-CD20 antibody
Abstract:	The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
Inventor(s):	White; Christine A. (Rancho Santa fe, CA), Grillo-Lopez; Antonio J. (Rancho Santa Fe, CA)
Assignee:	Biogen Inc. (Cambridge, MA)
Application Number:	14/310,167
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,504,744
Patent Claims:	1. A method of treating a >60 year old diffuse large cell lymphoma patient comprising administering anti-CD20 antibody and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) chemotherapy to the patient, wherein the anti-CD20 antibody is administered to the patient in combination with a transplantation regimen. 2. The method of claim 1, wherein the antibody comprises a chimeric anti-CD20 antibody. 3. The method of claim 2, wherein the antibody comprises rituximab. 4. The method of claim 1, wherein the lymphoma is accompanied by bone marrow involvement. 5. The method of claim 1, wherein the transplantation regimen comprises bone marrow transplantation. 6. The method of claim 1, wherein the anti-CD20 antibody and CHOP are administered simultaneously. 7. The method of claim 6, wherein the anti-CD20 antibody and CHOP are administered concurrently. 8. The method of claim 7, wherein the antibody comprises rituximab. 9. The method of claim 6, comprising administering the anti-CD20 antibody on Day 1 of each chemotherapy cycle and the CHOP on Day 1 of each chemotherapy cycle. 10. The method of claim 9, wherein the antibody comprises rituximab. 11. A method of treating a patient with diffuse large cell lymphoma comprising administering rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) chemotherapy to the patient, wherein the patient is >60 years old and wherein the rituximab and the CHOP are administered concurrently. 12. A method of treating a >60 year old diffuse large cell lymphoma patient comprising administering rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) chemotherapy to the patient, wherein the rituximab is administered on Day 1 of each chemotherapy cycle and the CHOP is administered on Day 1 of each chemotherapy cycle. 13. The method of claim 9 comprising administering six or eight chemotherapy cycles, wherein in each chemotherapy cycle a 375 mg/m.sup.2 dose of the anti-CD20 antibody is administered to the patient. 14. The method of claim 13 comprising administering eight chemotherapy cycles, wherein in each chemotherapy cycle a 375 mg/m.sup.2 dose of the anti-CD20 antibody is administered to the patient. 15. The method of claim 12 comprising administering six or eight chemotherapy cycles, wherein in each chemotherapy cycle a 375 mg/m.sup.2 dose of rituximab is administered to the patient. 16. The method of claim 15 comprising administering eight chemotherapy cycles, wherein in each chemotherapy cycle a 375 mg/m.sup.2 dose of rituximab is administered to the patient.

Details for Patent 9,504,744

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2019-08-11
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2019-08-11
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2019-08-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.